Locations:
Search IconSearch
October 14, 2019/Cancer/News & Insight

Jame Abraham, MD, FACP, Named Chair of Hematology/Medical Oncology

Renowned breast cancer researcher and editor to lead department

650×450-Jame-Abraham

Jame Abraham, MD, FACP, is the new Chair of Hematology/Medical Oncology at Cleveland Clinic.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

In his new position, Dr. Abraham will recruit and develop staff, and guide the department’s focus on patient access and multidisciplinary care. He also will continue as Professor of Medicine at Cleveland Clinic Lerner College of Medicine.

Most recently, Dr. Abraham was Director of the Breast Oncology Program at Cleveland Clinic’s Taussig Cancer Institute and Co-Director of the Cleveland Clinic Comprehensive Breast Cancer Program.

“Successfully leading our Hematology/Medical Oncology Department requires a leader who excels at empathy, fosters a culture of teamwork, demonstrates emotional intelligence and believes in the vision of our institute,” says Brian Bolwell, MD, Chairman, Taussig Cancer Institute, Cleveland Clinic Cancer Center. “Dr. Abraham represents these qualities and has exhibited a passion for department and caregiver development, and elevating our national reputation.”

About Dr. Abraham

Dr. Abraham earned his medical degree from Calicut Medical College in Kerala, India. He then completed a residency at the University of Connecticut, followed by a fellowship in hematology at the National Heart, Lung, and Blood Institute and a fellowship in medical oncology at the National Cancer Institute.

He worked as Chief of Hematology/Oncology, Professor of Medicine and Bonnie Wells Wilson Distinguished Professor of Breast Cancer Research at West Virginia University before joining Cleveland Clinic in 2013.

A national principal investigator of multiple breast cancer clinical trials, Dr. Abraham has published and presented more than 200 papers. He also is Founding Editor of The Bethesda Handbook of Clinical Oncology.

Advertisement

His national breast cancer committee and leadership activities include serving as:

  • Member of the National Comprehensive Cancer Network (NCCN) Breast Cancer Committee.
  • Vice Chair of NRG Oncology’s Research Strategy Committee.
  • Member of NRG Oncology’s Breast Cancer Working Committee.
  • Vice Chair of the National Surgical Adjuvant Breast and Bowel Project (NSABP) Research Review Committee.

“I look forward to building upon Cleveland Clinic Taussig Cancer Institute’s position as a leader in hematology and medical oncology, delivering outstanding, compassionate patient care and innovative research,” says Dr. Abraham. “I am honored to serve patients who choose Cleveland Clinic for advanced cancer treatment and to support the department’s committed and passionate caregivers.”

Advertisement

Related Articles

Physician checking patient's heart rate
July 15, 2026/Cancer

First-Generation BTK Inhibitors Associated with Higher Risk of Cardiac Events

Patients on ibrutinib were more than twice as likely to experience atrial fibrillation or heart failure than those on second-generation alternatives.

Thyroid cancer illustration
July 13, 2026/Cancer/News & Insight

New ASCO Guidelines Help Clinicians Navigate Rapid Shifts in Thyroid Cancer Treatment

Expert recommendations introduce use of targeted agents

AML cells in blood flow
July 10, 2026/Cancer/Blood Cancers

Ziftomenib + Chemotherapy Drives Deep Remission in Frontline NPM1-m/KMT2A-r AML

Combination therapy may soon represent new standard of care

Researcher with microscope
June 26, 2026/Cancer

Testosterone May Offer Anti-Tumor Activity in Glioblastoma

Research findings offer clues for improving disease outcomes in men

Male patient with doctor
June 17, 2026/Cancer/Patient Support

Overcoming Taboos: Helping Men with Cancer Restore Sexual Health

Creating a safe space for patients

Masked patient with physician
June 15, 2026/Cancer/Patient Support

Managing Infection Risk in the Era of Cell Therapy

Long-term immune effects reshape preventative strategies and timelines

Immune checkpoint inhibitor illustration
June 12, 2026/Cancer/News & Insight

Immunotherapy Appears to Reduce the Risk of Secondary Primary Cancers

Large-scale database also reveals potential for immunotherapy to protect against cancer

T53 mutation illustration
June 10, 2026/Cancer/News & Insight

TP53 Mutation Acquisition Timing Influences Prognosis in Myeloproliferative Neoplasms

Findings may help guide discussions around prognosis and allogeneic stem cell transplantation

Ad